Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndrome

Metabolism: Clinical and Experimental

Volumn 55, Issue 12, 2006, Pages 1582-1589

  Glueck, Charles J ^a   Aregawi, Dawit ^a   Agloria, Mahlia ^a   Winiarska, Magdalena ^a   Sieve, Luann ^a   Wang, Ping ^a  

^a JEWISH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TRIACYLGLYCEROL;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; ATHEROGENESIS; BODY MASS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HOMEOSTASIS; HUMAN; HYPOTHESIS; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT REDUCTION;

ATHEROSCLEROSIS; BODY MASS INDEX; CHOLESTEROL, HDL; CHOLESTEROL, LDL; ENERGY INTAKE; FEMALE; HUMANS; INSULIN RESISTANCE; METFORMIN; POLYCYSTIC OVARY SYNDROME; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RISK FACTORS; WEIGHT LOSS;

EID: 34249716122     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2006.08.001     Document Type: Article

References (72)

1. Knochenhauer E.S., Key T.J., Kahsar-Miller M., et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 83 (1998) 3078-3082
2. Goodarzi M.O., Quinones M.J., Azziz R., et al. Polycystic ovary syndrome in Mexican-Americans: prevalence and association with the severity of insulin resistance. Fertil Steril 84 (2005) 766-769
3. Azziz R., Woods K.S., Reyna R., et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89 (2004) 2745-2749
4. Glueck C.J., Dharashivkar S., Wang P., et al. Obesity and extreme obesity, manifest by ages 20-24 years, continuing through 32-41 years in women, should alert physicians to the diagnostic likelihood of polycystic ovary syndrome as a reversible underlying endocrinopathy. Eur J Obstet Gynecol Reprod Biol 122 (2005) 206-212
5. Vryonidou A., Papatheodorou A., Tavridou A., et al. Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 90 (2005) 2740-2746
6. Lakhani K., Hardiman P., and Seifalian A.M. Intima-media thickness of elastic and muscular arteries of young women with polycystic ovaries. Atherosclerosis 175 (2004) 353-359
7. Legro R.S. Polycystic ovary syndrome and cardiovascular disease: a premature association?. Endocr Rev 24 (2003) 302-312
8. Macut D., Micic D., Cvijovic G., et al. Cardiovascular risk in adolescent and young adult obese females with polycystic ovary syndrome (PCOS). J Pediatr Endocrinol Metab 14 Suppl 5 (2001) 1353-1359 [discussion 1365]
9. Glueck C.J., Papanna R., Wang P., et al. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 52 (2003) 908-915
10. Lo J.C., Feigenbaum S.L., Yang J., et al. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab 91 (2006) 1357-1363
11. Crave J.C., Fimbel S., Lejeune H., et al. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab 80 (1995) 2057-2062
12. Moran L.J., Noakes M., Clifton P.M., et al. Short term energy restriction (using meal replacements) improves reproductive parameters in polycystic ovary syndrome. Asia Pac J Clin Nutr 13 (2004) S88
13. Pasquali R., Antenucci D., Casimirri F., et al. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 68 (1989) 173-179
14. Hoeger K.M., Kochman L., Wixom N., et al. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril 82 (2004) 421-429
15. Velazquez E.M., Mendoza S., Hamer T., et al. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 43 (1994) 647-654
16. Velazquez E., Acosta A., and Mendoza S.G. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 90 (1997) 392-395
17. Velazquez E.M., Mendoza S.G., Wang P., et al. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism 46 (1997) 454-457
18. Fleming R., Hopkinson Z.E., Wallace A.M., et al. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab 87 (2002) 569-574
19. Morin-Papunen L.C., Koivunen R.M., Ruokonen A., et al. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 69 (1998) 691-696
20. Stamets K., Taylor D.S., Kunselman A., et al. A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. Fertil Steril 81 (2004) 630-637
21. Crosignani P.G., Colombo M., Vegetti W., et al. Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod 18 (2003) 1928-1932
22. Tolino A., Gambardella V., Caccavale C., et al. Evaluation of ovarian functionality after a dietary treatment in obese women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 119 (2005) 87-93
23. Moran L.J., Noakes M., Clifton P.M., et al. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 88 (2003) 812-819
24. Moran L.J., Noakes M., Clifton P.M., et al. Ghrelin and measures of satiety are altered in polycystic ovary syndrome but not differentially affected by diet composition. J Clin Endocrinol Metab 89 (2004) 3337-3344
25. Norman R.J., Davies M.J., Lord J., et al. The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab 13 (2002) 251-257
26. Pasquali R., Gambineri A., Biscotti D., et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 85 (2000) 2767-2774
27. Goldenberg N., Glueck C.J., Loftspring M., et al. Metformin-diet benefits in women with polycystic ovary syndrome in the bottom and top quintiles for insulin resistance. Metabolism 54 (2005) 113-121
28. Glueck C.J., Wang P., Fontaine R., et al. Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). J Adolesc Health 29 (2001) 160-169
29. Trent M., Austin S.B., Rich M., et al. Overweight status of adolescent girls with polycystic ovary syndrome: body mass index as mediator of quality of life. Ambul Pediatr 5 (2005) 107-111
30. Li S., Chen W., Srinivasan S.R., et al. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. JAMA 290 (2003) 2271-2276
31. Freedman D.S., Dietz W.H., Tang R., et al. The relation of obesity throughout life to carotid intima-media thickness in adulthood: the Bogalusa Heart Study. Int J Obes Relat Metab Disord 28 (2004) 159-166
32. Steinberger J., Moran A., Hong C.P., et al. Adiposity in childhood predicts obesity and insulin resistance in young adulthood. J Pediatr 138 (2001) 469-473
33. Flegal K.M., Carroll M.D., Ogden C.L., et al. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288 (2002) 1723-1737
34. The Rotterdam ESHRE/ASRM-Sponsored PCOs Consensus Work Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81 (2004) 19-25
35. Ferriman D., and Gallwey J.D. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21 (1961) 1440-1447
36. Glueck C.J., Streicher P., and Wang P. Treatment of polycystic ovary syndrome with insulin-lowering agents. Expert Opin Pharmacother 3 (2002) 1177-1189
37. Glueck C.J., Wang P., Goldenberg N., et al. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 17 (2002) 2858-2864
38. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
39. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287 (2002) 356-359
40. Glueck C.J., Wang P., Fontaine R., et al. Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism 48 (1999) 511-519
41. Harborne L., Fleming R., Lyall H., et al. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab 88 (2003) 4116-4123
42. Ibanez L., and de Zegher F. Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy. J Clin Endocrinol Metab 90 (2005) 39-43
43. Moghetti P., Castello R., Negri C., et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 85 (2000) 139-146
44. Sepilian V., and Nagamani M. Adiponectin levels in women with polycystic ovary syndrome and severe insulin resistance. J Soc Gynecol Investig 12 (2005) 129-134
45. Spranger J., Mohlig M., Wegewitz U., et al. Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 61 (2004) 738-746
46. Nestler J.E., Powers L.P., Matt D.W., et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 72 (1991) 83-89
47. Nestler J.E., Jakubowicz D.J., de Vargas A.F., et al. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 83 (1998) 2001-2005
48. Nestler J.E., and Jakubowicz D.J. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab 82 (1997) 4075-4079
49. Nestler J.E. Insulin resistance syndrome and polycystic ovary syndrome. Endocr Pract 9 Suppl 2 (2003) 86-89
50. Nestler J.E. Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications. Semin Reprod Endocrinol 15 (1997) 111-122
51. Baillargeon J.P., Jakubowicz D.J., Iuorno M.J., et al. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 82 (2004) 893-902
52. Baillargeon J.P., Iuorno M.J., and Nestler J.E. Insulin sensitizers for polycystic ovary syndrome. Clin Obstet Gynecol 46 (2003) 325-340
53. Harborne L.R., Sattar N., Norman J.E., et al. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab 90 (2005) 4593-4598
54. Ehrmann D.A., Cavaghan M.K., Imperial J., et al. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 82 (1997) 524-530
55. Sahin I., Serter R., Karakurt F., et al. Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study. Gynecol Endocrinol 19 (2004) 115-124
56. Ibanez L., Valls C., Ferrer A., et al. Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J Clin Endocrinol Metab 86 (2001) 3595-3598
57. Maciel G.A., Soares J., Junior M., Alves da Motta E.L., et al. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil Steril 81 (2004) 355-360
58. Torgerson J.S., Hauptman J., Boldrin M.N., et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27 (2004) 155-161
59. Jayagopal V., Kilpatrick E.S., Holding S., et al. Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. J Clin Endocrinol Metab 90 (2005) 729-733
60. De Leo V., la Marca A., and Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 24 (2003) 633-667
61. Chou K.H., von Eye H., Corleta E., et al. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial. Horm Metab Res 35 (2003) 86-91
62. Talbott E.O., Zborowskii J.V., and Boudraux M.Y. Do women with polycystic ovary syndrome have an increased risk of cardiovascular disease? Review of the evidence. Minerva Ginecol 56 (2004) 27-39
63. Talbott E.O., Zborowski J.V., Rager J.R., et al. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 89 (2004) 5454-5461
64. Talbott E.O., Guzick D.S., Sutton-Tyrrell K., et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 20 (2000) 2414-2421
65. Tamsma J.T., Jazet I.M., Beishuizen E.D., et al. The metabolic syndrome: a vascular perspective. Eur J Intern Med 16 (2005) 314-320
66. Jermendy G. Can type 2 diabetes mellitus be considered preventable?. Diabetes Res Clin Pract 68 Suppl 1 (2005) S73-S81
67. Ramachandran A., Snehalatha C., Mary S., et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia (2006) 1-9
68. Laakso M. Prevention of type 2 diabetes. Curr Mol Med 5 (2005) 365-374
69. Padwal R., Majumdar S.R., Johnson J.A., et al. A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care 28 (2005) 736-744
70. AndersonJr D.C. Pharmacologic prevention or delay of type 2 diabetes mellitus. Ann Pharmacother 39 (2005) 102-109
71. Hess A.M., and Sullivan D.L. Metformin for prevention of type 2 diabetes. Ann Pharmacother 38 (2004) 1283-1285
72. Kiddy D.S., Hamilton-Fairley D., Bush A., et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 36 (1992) 105-111